BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer.
BMB Rep
; 51(8): 373-377, 2018 Aug.
Article
in En
| MEDLINE
| ID: mdl-29898809
ABSTRACT
Triple-negative breast cancer (TNBC) is considered to be a notorious type of cancer due to its aggressive metastatic potential and poor prognosis. Recent evidence suggests that BLT2, a low-affinity LTB4 receptor is critically associated with the phenotypes of TNBC cells, including invasion, metastasis, and survival. Furthermore, in a group of 545 breast cancer patients with metastasis, we observed that the high-BLT2 subgroup had a lower disease-free-survival rate than the low-BLT2 subgroup. Thus, we theorized that anti-BLT2 strategies could facilitate the development of new therapies used for TNBC. This review focuses on recent discoveries regarding BLT2 and its roles in as a novel prognostic biomarker in TNBC. [BMB Reports 2018; 51(8) 373-377].
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Receptors, Leukotriene B4
/
Triple Negative Breast Neoplasms
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
BMB Rep
Journal subject:
BIOLOGIA MOLECULAR
/
BIOQUIMICA
Year:
2018
Document type:
Article